CCR4 as a novel molecular target for immunotherapy of cancer

Cancer Science

Volumn 97, Issue 11, 2006, Pages 1139-1146

  Ishida, Takashi ^a   Ueda, Ryuzo ^a  

^a NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; CD20 ANTIGEN; CETUXIMAB; CHEMOKINE; CHEMOKINE RECEPTOR; CHEMOKINE RECEPTOR CCR4; CHEMOKINE RECEPTOR CCR4 MONOCLONAL ANTIBODY; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FC RECEPTOR; KM 2760; KM 3060; MACROPHAGE DERIVED CHEMOKINE; MONOCLONAL ANTIBODY; RITUXIMAB; THYMUS AND ACTIVATION REGULATED CHEMOKINE; TRASTUZUMAB; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTINEOPLASTIC ACTIVITY; B CELL LYMPHOMA; BINDING AFFINITY; BREAST CANCER; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CELL FUNCTION; CELL INFILTRATION; CLINICAL TRIAL; COLORECTAL CANCER; CYTOKINE PRODUCTION; DRUG STRUCTURE; DRUG TARGETING; EFFECTOR CELL; HEAD AND NECK CARCINOMA; HUMAN; IMMUNE RESPONSE; JAPAN; LEUKOCYTE MIGRATION; METASTASIS POTENTIAL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR BINDING; REGULATORY T LYMPHOCYTE; REVIEW; SQUAMOUS CELL CARCINOMA; T CELL LEUKEMIA; T CELL LYMPHOMA; TUMOR CELL; TUMOR ESCAPE; TUMOR IMMUNITY;

HUMANS; IMMUNOTHERAPY; NEOPLASMS; RECEPTORS, CHEMOKINE; T-LYMPHOCYTES;

EID: 33748933230     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2006.00307.x     Document Type: Review

References (51)

1. Yoshie O, Imai T, Nomiyama H. Chemokines in immunity. Adv Immunol 2001; 78: 57-110.
2. Mosmann TR, Sad S. The expanding universe of T-cell subsets: Th1, Th2 and more. Immunol Today 1996; 17: 138-46.
3. O'Garra A, Vieira P. Regulatory T cells and mechanisms of immune system control. Nat Med 2004; 10: 801-5.
4. Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science 2003; 299: 1057-61.
5. Zou W. Regulatory T cells, tumor immunity and immunotherapy. Nat Rev Immunol 2006; 6: 295-307.
6. Zou W. Immunosuppressive networks in the tumor environment and their therapeutic relevance. Nat Rev Cancer 2005; 5: 263-74.
7. Imai T, Nagira M, Takagi S et al. Selective recruitment of CCR4-bearing Th2 cells toward antigen-presenting cells by the CC chemokines thymus and activation-regulated chemokine and macrophage-derived chemokine. Int Immunol 1999; 11: 81-8.
8. + regulatory T cells. J Exp Med 2001; 194: 847-53.
9. Curiel TJ, Coukos G, Zou L et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004; 10: 942-9.
10. + regulatory T cells. Int Immunol 2005; 16: 1643-56.
11. Kikuchi M, Jaffe ES, Ralfkiaer E. Adult T-cell leukaemia/lymphoma. In: Jaffe ES, Harris NL, Stein H, Vardiman JW, eds. Pathology and Genetics Tumors of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press 2001, 200-3.
12. Yoshie O, Fujisawa R, Nakayama T et al. Frequent expression of CCR4 in adult T-cell leukemia and human T-cell leukemia virus type 1-transformed T cells. Blood 2002; 99: 1505-11.
13. Ishida T, Utsunomiya A, Iida S et al. Clinical significance of CCR4 expression in adult T-cell leukemia/lymphoma: Its close association with skin involvement and unfavorable outcome. Clin Cancer Res 2003; 9: 3625-34.
14. Müller A, Homey B, Soto H et al. Involvement of chemokine receptors in breast cancer metastasis. Nature 2001; 410: 50-6.
15. Girardi M, Heald PW, Wilson LD. The pathogenesis of mycosis fungoides. N Engl J Med 2004; 350: 1978-88.
16. Karube K, Ohshima K, Tsuchiya T et al. Expression of FoxP3, a key molecule in CD4CD25 regulatory T cells, in adult T-cell leukaemia/ lymphoma cells. Br J Hematol 2004; 126: 81-4.
17. Ishida T, Iida S, Akatsuka Y et al. The CC chemokine receptor 4 as a novel specific molecular target for immunotherapy in adult T-cell leukemia/lymphoma. Clin Cancer Res 2004; 10: 7529-39.
18. Kohno T, Yamada Y, Akamatsu N et al. Possible origin of adult T-cell leukemia/lymphoma cells from human T lymphotropic virus type-1-infected regulatory T cells. Cancer Sci 2005; 96: 527-33.
19. Roncador G, Garcia JF, Garcia JF et al. FOXP3, a selective marker for a subset of adult T-cell leukaemia/lymphoma. Leukemia 2005; 19: 2247-53.
20. + adult T cell leukemia cells. Int Immunol 2006; 18: 269-77.
21. Jones D, O'Hara C, Kraus MD et al. Expression pattern of T-cell-associated chemokine receptors and their chemokines correlates with specific subtypes of T-cell non-Hodgkin lymphoma. Blood 2000; 96: 685-90.
22. Ishida T, Inagaki H, Utsunomiya A et al. CXCR3 and CCR4 expression in T-cell and NK-cell lymphomas with special reference to clinicopathological significance for peripheral T-cell lymphoma, unspecified. Clin Cancer Res 2004; 10: 5494-500.
23. Ohshima K, Karube K, Kawano R et al. Classification of distinct subtypes of peripheral T-cell lymphoma unspecified, identified by chemokine and chemokine receptor expression: Analysis of prognosis. Int J Oncol 2004; 25: 605-13.
24. Ishida T, Inagaki H, Kusumoto S et al. CC chemokine receptor 4-positive diffuse large B-cell lymphoma involving the skin: A case report. Int J Hematol 2005; 82: 148-51.
25. Stein H, Mann R, Delsol G et al. Classical Hodgkin lymphoma. In: Jaffe ES, Harris NL, Stein H, Vardiman JW, eds. Pathology and Genetics Tumors of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press 2001, 244-53.
26. Ishida T, Ishii T, Inagaki A et al. Specific recruitment of CCR4-positive regulatory T cells in Hodgkin lymphoma fosters immune privilege. Cancer Res 2006; 66: 5716-22.
27. van den Berg A, Visser L, Poppema S. High expression of the CC chemokine in Reed-Sternberg cells. A possible explanation for the characteristic T-cell infiltrate in Hodgkin's lymphoma. Am J Pathol 1999; 154: 1685-91.
28. Weihrauch MR, Manzke O, Beyer M et al. Elevated serum levels of CC thymus and activation-related chemokine (TARC) in primary Hodgkin's disease: Potential for a prognostic factor. Cancer Res 2005; 65: 5516-19.
29. Maggio EM, van den Berg A, Visser L et al. Common and differential chemokine expression patterns in rs cells of NLP, EBV positive and negative classical Hodgkin lymphomas. Int J Cancer 2002; 99: 665-72.
30. + T cells by producing CCL22. Eur J Immunol 2002; 32: 1403-13.
31. +CD25hi regulatory T cells in patients with chronic lymphocytic leukemia after therapy with fludarabine. Blood 2005; 106: 2018-24.
32. Nakayama T, Hieshima K, Nagakubo D et al. Selective Induction of Th2-attracting chemokines CCL17 and CCL22 in human B cells by latent membrane protein 1 of Epstein-Barr virus. J Virol 2004; 78: 1665-74.
33. Slamon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344: 783-92.
34. Coiffier B, Lepage E, Briere J et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002; 346: 235-42.
35. Hurwitz H, Fehrenbacher L, Novotny W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335-42.
36. Bonner JA, Harari PM, Giralt J et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006; 354: 567-78.
37. Carter P. Improving the efficacy of antibody-based cancer therapies. Nat Rev Cancer 2001; 1: 118-29.
38. Cartron G, Dacheux L, Salles G et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcRIIIa gene. Blood 2002; 99: 754-8.
39. Gennari R, Menard S, Fagnoni F et al. Pilot study of the mechanism of action of preoperative trastuzumab in patients with primary operable breast tumors overexpressing HER2. Clin Cancer Res 2004; 10: 5650-5.
40. Rademacher TW, Homans SW, Parekh RB, Dwek RA. Immunoglobulin G as a glycoprotein. Biochem Soc Symp 1986; 51: 131-48.
41. Jefferis R, Lund J, Pound JD. IgG-Fc-mediated effector functions: molecular definition of interaction sites for effector ligands and the role of glycosylation. Immunol Rev 1998; 163: 59-76.
42. Kumpel BM, Wang Y, Griffiths HL, Hadley AG, Rook GA. The biological activity of human monoclonal IgG anti-D is reduced by β-galactosidase treatment. Hum Antibodies Hybridomas 1995; 6: 82-8.
43. Umana P, Jean-Mairet J, Moudry R, Amstutz H, Bailey JE. Engineered glycoforms of an antineuroblastoma IgG1 with optimized antibody-dependent cellular cytotoxic activity. Nat Biotechnol 1999; 17: 176-80.
44. Shields RL, Lai J, Keck R et al. Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human FcRIII and antibody-dependent cellular toxicity. J Biol Chem 2002; 277: 26 733-40.
45. Shinkawa T, Nakamura K, Yamane N et al. The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity. J Biol Chem 2003; 278: 3466-73.
46. Niwa R, Sakurada M, Kobayashi Y et al. Enhanced natural killer cell binding and activation by low-fucose IgG1 antibody results in potent antibody-dependent cellular cytotoxicity induction at lower antigen density. Clin Cancer Res 2005; 11: 2327-36.
47. Niwa R, Shoji-Hosaka E, Sakurada M et al. Defucosylated chimeric anti-CCR4 IgG1 with enhanced antibody-dependent cellular cytotoxicity shows potent therapeutic activity to T cell leukemia and lymphoma. Cancer Res 2004; 64: 2127-33.
48. + T cells: A common basis between tumor immunity and autoimmunity. J Immunol 1999; 163: 5211-18.
49. + T-cell-dependent immune defense of B16 melanoma. Cancer Res 2001; 61: 8643-6.
50. Sanderson K, Scotland R, Lee P et al. Autoimmunity in a phase I trial of a fully human anti-cytotoxic T-lymphocyte antigen-4 monoclonal antibody with multiple melanoma peptides and Montanide ISA 51 for patients with resected stages III and IV melanoma. J Clin Oncol 2005; 23: 741-50.
51. Wood AJ, Darbyshire J. Injury to research volunteers - The clinical-research nightmare. N Engl J Med 2006; 354: 1869-71.